Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Dec 19, 2027
  • participants needed
    297
  • sponsor
    EBG MedAustron GmbH
Send
Updated on 7 October 2022
See if I qualify

Summary

This prospective study assess the effectiveness and safety of hypofractionated proton radiotherapy in the treatment of intermediate and low risk prostate cancer.

Description

The purpose of this study is to assess the effectiveness and safety of spot-scanning based hypofractionated proton radiotherapy for the treatment of intermediate and low risk prostate cancer. The treatment effectiveness is defined as freedom from biochemical failure. Treatment safety will be documented with acute and late morbidity assessments. Dose volume relationships for late side effects in organs at risk surrounding the prostate will be calculated from the dose volume histogram parameters assessed during treatment planning. Patient assessed Quality of life data including sexual function will be collected to increase our understanding how the reduction of normal tissue irradiation with proton therapy with subsequent decrease in functional impairments will overall affect the patient's life.

Details
Condition Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
Treatment EPIC questionnaire, kV x-ray images, Conebeam CT
Clinical Study IdentifierNCT03740191
SponsorEBG MedAustron GmbH
Last Modified on7 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Pathological (histologically) proven diagnosis of prostatic adenocarcinoma
Clinical stage T1-T2b
Prostate specific antigen (PSA) ≤ 20 ng/mL
Gleason Score ≤ 7
Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
Clinically negative lymph nodes evaluated by imaging (pelvic +/- abdominal CT or MRI scan)
Any patient with lymph nodes > 1.0 cm maximum diameter requires further studies to address eligibility. Positron emission tomography (PET)-CT is recommended for lymph nodes > 1.0 cm. Positive PET-CT indicates malignant involvement. Hence, the patient will be staged as "high-risk" and therefore declared ineligible for study participation. Negative PET-CT in lymph nodes 1.0-1,5 cm indicates non-involvement and thus eligibility. Negative PET-CT in lymph nodes > 1.5 cm is equivocal and requires additional work-up, preferably by biopsy
Patients must be 18 years of age or older. There is no upper age limit
Patient must be able to provide study-specific informed consent prior to study entry
Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) Questionnaire to assess Quality of Life
Previously initiated Androgen Deprivation Therapy (ADT) is acceptable
Patients with history of chronic bowel diseases may be included
Patients with previous Transurethral Resection of the Prostate (TURP) performed for urinary retention may be included

Exclusion Criteria

Prior radiotherapy to the pelvic area
Prior prostate cancer therapy such as: prostatectomy, cryotherapy or hyperthermia
Prior systemic therapy (chemotherapy) for prostate cancer
Concurrent cytotoxic chemotherapy for prostate cancer
Evidence of distant metastases
Regional lymph node involvement
International Prostate Symptom Score (IPSS) > 20
Hip prosthesis
Second invasive malignancy (except of basal cell and squamous cell carcinoma of the skin in situ) if not controlled within last two years
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note